Search results
Results From The WOW.Com Content Network
Simvastatin also reduced the numbers of other events like heart attacks, strokes, and revascularizations and MI significantly. [11] The Heart Protection Study evaluated the effects of simvastatin in people with risk factors including existing cardiovascular disease, diabetes, or stroke, but having relatively low LDL cholesterol. In this trial ...
Dirlotapide is used to manage obesity in dogs and helps by reducing appetite. It is used as part of an overall weight control program that also includes proper diet and exercise, under the supervision of a veterinarian. Side effects may include vomiting, diarrhea, lethargy, drooling, or uncoordination.
Simvastatin: No tumorigenic effect was seen in a 72-week carcinogenicity study using mice at the low dose levels. However, at the higher dose levels (eight and 16 times the human dose equivalent), liver carcinomas and adenomas, lung adenomas, and adenomas of the Harderian gland occurred.
FDA Issues Urgent Warning on Dangers of Common Dog Medication. Genny Glassman. December 20, 2024 at 1:50 PM ... The F.D.A. now says that the drug Librela may be associated with severe neurological ...
The symptoms of poisoning vary depending on substance, the quantity a dog has consumed, the breed and size of the mammal.A common list of symptoms are digestion problems, such as vomiting, diarrhea, or blood in stool; bruising and bleeding gums, nose, or inside the ear canal; behavioral changes, such as lethargy, hyperactivity, and seizures; unusual items found in the dog's stool.
In this latter group, statin assignment was not automatic, but was recommended to occur only after a clinician-patient risk discussion with shared decision making where other risk factors and lifestyle are addressed, the potential for benefit from a statin is weighed against the potential for adverse effects or drug interactions and informed ...
Some of the most popular dog toys are actually very dangerous. Skip to main content. Sign in. Mail. 24/7 Help. For premium support please call: 800-290-4726 more ways to reach us ...
With median follow-up of 6 years, simvastatin+ezetimibe was found to reduce the primary outcome of CV mortality, major CV event, or nonfatal stroke (34.7% vs. 32.7%; P=0.016; NNT 50 per 7 years or NNT 350 per 1 year ). There was no reduction in all-cause or CV mortality with simvastatin+ezetimibe, though there was a reduction in MI and stroke. [6]